Translator: Theresa  by Vancouver sailing Farm Canada

This article is excerpted from 13 clinical medical experts and scholars including Bangladesh Medical College (Affiliated) Hospital and Bangladesh Shomman Foundation Mohammed Tarek Alam published in the European Journal of Medicine and Health Sciences on December 15, 2020 Medical and Health Sciences) paper “Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study”.

Picture from :Wfla.com

The article introduces that from May 2020 to August 2020, at the Bangladesh Medical College Hospital (tertiary hospital) in Dhaka, Bangladesh, 118 patients with confirmed COVID-19 who were interested in testing Ivermectin were tested. Observational studies conducted by healthcare workers working in quarantine.

One hundred eighteen subjects were divided into the experimental group of 58 and the control group of 60. In the continuous 4-month trial, the experimental group received 12 mg of Ivermectin per month. During the course of the study, both groups had close contact with hospitalized patients who were positive for COVID-19.

The results showed that 44 of the 60 people in the control group were infected with COVID-19, while only 4 of the 58 people in the experimental group were infected. Explain that oral Ivermectin can prevent COVID-19 infection. No one has reported any side effects of Ivermectin.

The results showed that 44 of the 60 people in the control group were infected with COVID-19, while only 4 of the 58 people in the experimental group were infected. Explain that oral ivermectin can prevent COVID-19 infection. No one has reported any side effects of ivermectin.

Age: Of the 118 participants, most of them were women, the oldest was 60 years old and the youngest was 25 years old, and most participants were between 25 and 40 years old. The mean ages of the experimental and control groups were 37.1 and 36.7 years, respectively.

Gender: Among the 58 participants in the experimental group, 16 were male, accounting for 27.6%, and 42 were female, accounting for 72.4%. In the control group of 60 participants, 26 were male, accounting for 43.3%, and 34 were female, accounting for 56.7%.

Occupation: 18 doctors, 10 interns, 18 nurses, and 12 waiters in the experimental group, and 11 doctors, 8 interns, 22 nurses, and 19 waiters in the control group.

Smoking history: The experimental group consisted of 12 smokers and 46 non-smokers, and the control group consisted of 13 smokers and 47 non-smokers.

History of other comorbidities: 20 people in the experimental group had a history of comorbidities before, accounting for 34.5%, and 18 people in the control group, accounting for 30%.

Contact history with family members who are positive for COVID-19: 11 people in the experimental group, accounting for 19%, and 7 people in the control group, accounting for 12.1%.

The final result is as follows:

Despite exposure to patients who tested positive for COVID-19 RT-PCR, by the end of the study, 54 of the 58 participants in the experimental group, or 93.1%, remained healthy, and only 4 participants, or 6.9% developed symptoms.

On the contrary, the 60 participants in the control group had not been given the prophylactic dose of Ivermectin since the start of the trial, and 44 in the control group developed symptoms of COVID-19 at various stages of the study and were tested for COVID-19 by RT-PCR. -19 was positive, accounting for 73.3%. See the table below.

Of the 4 people infected with COVID-19 in the test group, 3 were women, aged 21-40, and 1 was a man, aged 51-60. All four infected people had mild symptoms, including low grade fever, dry cough and weakness. In addition, 2 of the 4 participants underwent HRCT of the chest, which showed bilateral pulmonary infiltrates HRCT findings consistent with COVID-19. As shown below.

Of the 44 infected people in the control group, most belonged to the 21-30 age group. In particular, it should be pointed out that 22 of the 26 men in the control group were infected, accounting for 84.6%. The specific age distribution is shown in the figure below.

Throughout the testing process, no one reported any side effects or complained about the rationale for the Ivermectin dosing regimen.

The pathogen of COVID-19, SARS-CoV2, is a single stranded positive sense Ribonucleic acid (RNA) virus. The research results of Sharun K et al. (Ivermectin, a new candidate therapeutic against SARS) -CoV-2/COVID-19) showed that IMPα/β1 binds to the coronavirus protein in the cytoplasm and transfers it to the nucleus, where the complex disintegrates, thereby disintegrating the virus Released from the complex, it enables it to reduce the antiviral response of the host cell, resulting in enhanced infection.

Ivermectin binds to and destabilizes the Impα/β1 heterodimer, thereby preventing Impα/β1 from binding to viral proteins and in the process preventing the virus from entering the nucleus. Vero-hSLAM cells were infected with SARS-CoV-2 for 2 hours and treated with Ivermectin, resulting in a ~5000-fold reduction in viral RNA after 48 hours. This results in fewer infections and increased antiviral responses.

Since Ivermectin has potent antiviral properties and has also been shown to be effective in preventing and eliminating parasitic diseases by mass dosing with negligible side effects, we can apply it in the prevention of COVID-19, where the viruses are prevented and mitigated long before the disease process is initiated and further death is caused.

Reference:

Author: Michael.Tonny by Vancouver sailing Farm Canada

Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

European Journal of Medical and Health Sciences

Editor: Gerald Garwood         Publish: Winner为自由而战(文祥)